Ipilimumab and nivolumab induction in PDIGREE: step 1 findings in mccRCC

0 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Tian Zhang, MD, UT Southwestern Medical Center, Dallas, TX, describes results from step 1 of the PDIGREE trial (NCT03793166), which evaluated first-line ipilimumab and nivolumab in patients with metastatic clear cell renal cell carcinoma (mccRCC). This interim analysis highlights patient demographics, treatment discontinuation reasons, and safety outcomes. Most patients progressed to step 2, with a minority achieving early complete response or experiencing progression. Treatment-related adverse events were consistent with prior findings. These data offer insight into real-world tolerability and early responses to ipilimumab and nivolumab induction in a diverse American population. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Category
Oncology
Be the first to comment

Up Next